Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

ValiRx Signs Drug Transfer Agreement With Japanese Pharma Firm

Fri, 01st May 2020 14:23

(Alliance News) - ValiRx on Friday said it has signed a material transfer agreement with a Japanese pharmaceutical company in relation to VAL301.

VAL301 - derived from ValiRx's lead compound, VAL201 - is intended as non-invasive treatment for endometriosis, a gynaecological disorder in which tissue which normally lines the inside of the uterus starts to grow outside of it. The condition stands as one of the major causes of female infertility.

The biotechnology company said the agreement signed with the undisclosed company will see VAL301 evaluated for the purpose of contemplating a potential future license for the treatment of endometriosis. It added that the company has already reviewed ValiRx's prior data and now wishes to use further data to conduct its own experiments.

The undisclosed company has a range of pre-clinical assays for testing drug candidates for use in the treatment of endometriosis, as well as several commercial and developmental products in women's health, and other healthcare areas, ValiRx noted.

Under the terms of the material transfer agreement, ValiRx will supply VAL301 while the Japanese company will be responsible for undertaking an agreed programme of work at its own expense.

In a separate statement, London-based ValiRx noted the recent movement in its share price, adding that it believes that any placing conducted will have to be at a price likely to be at a "significant" discount to its current stock price.

Earlier in April, the company said it was reviewing ways to raise funds to improve its "extremely weak" capital position.

Shares in Chelmsford-based ValiRx were trading 2.9% higher at 13.50 pence each on Friday afternoon in London.

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News
21 Mar 2024 11:22

ValiRx inks evaluation deal with Imperial College London for research

(Alliance News) - ValiRx PLC on Thursday said that it has signed an evaluation deal with Imperial College London to look at research on novel therapeu...

19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

13 Feb 2024 14:45

ValiRx says requisition notice from shareholder group is invalid

(Alliance News) - ValiRx PLC on Tuesday said a requisition notice, which it received earlier in February, has been confirmed as invalid following lega...

12 Feb 2024 12:59

ValiRx inks deal with Dundee Drug Discovery Unit

(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.

12 Feb 2024 11:42

IN BRIEF: ValiRx signs research sharing deal with Dundee University

ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Signs agreement with Dundee University's drug ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.